Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
11.50
-0.16 (-1.37%)
Nov 3, 2025, 9:52 AM EST - Market open
Ocular Therapeutix Revenue
Ocular Therapeutix had revenue of $13.46M in the quarter ending June 30, 2025, a decrease of -18.14%. This brings the company's revenue in the last twelve months to $56.66M, down -7.26% year-over-year. In the year 2024, Ocular Therapeutix had annual revenue of $63.72M with 9.03% growth.
Revenue (ttm)
$56.66M
Revenue Growth
-7.26%
P/S Ratio
34.84
Revenue / Employee
$206,803
Employees
274
Market Cap
2.44B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 63.72M | 5.28M | 9.03% |
| Dec 31, 2023 | 58.44M | 6.95M | 13.49% |
| Dec 31, 2022 | 51.49M | 7.97M | 18.32% |
| Dec 31, 2021 | 43.52M | 26.12M | 150.08% |
| Dec 31, 2020 | 17.40M | 13.18M | 311.71% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
OCUL News
- 27 days ago - Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences - GlobeNewsWire
- 4 weeks ago - Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript - Seeking Alpha
- 4 weeks ago - Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock - GlobeNewsWire
- 4 weeks ago - Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint - GlobeNewsWire
- 7 weeks ago - Ocular Therapeutix, Inc. (OCUL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 2 months ago - Ocular Therapeutix: A High-Stakes Bet On Becoming The New Standard Of Care - Seeking Alpha
- 3 months ago - Ocular Therapeutix, Inc. (OCUL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company - GlobeNewsWire